Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- 177Lu-PSMA-617 (Pluvicto) Combo With Sipulecel-T in Phase 1 Trial November 1, 2025
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
OST11098: A Promising New Approach for Castration-Resistant Prostate Cancer
/in Preclinical Research/by MaxPhase 1 Trial: APG-5918 an EED Inhibitor for Prostate Cancer Therapy
/in Clinical Trial, Metastatic, Phase 1/by MaxSHR3591 Shows Promise in Tackling Resistant Prostate Cancer
/in Preclinical Research, PROTACs/by MaxPhase 1 Trial: CTS2190 Targets Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial: SYN818 Shows Promise for Prostate Cancer Patients With HRR Genetic Mutations
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: NXP900 for Overcoming Resistance in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: ABBV-969, A Novel Bispecific Antibody Drug Conjugate for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: GDC-2992, A Novel Dual-Action AR Degrader Aiming to Overcome Resistance in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by Max